Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers

开发 CDK12 抑制剂以克服 HER2 和 KRAS 驱动的乳腺癌和肺癌的治疗耐药性

基本信息

项目摘要

Project Summary Although the development of targeted therapies has improved overall cancer patient survival, adaptive responses by tumor cells can render these treatments ineffective. The development of agents that block adaptive responses, thereby increasing treatment durability is desperately needed. We and others have demonstrated that inhibitors of the transcriptional cyclin-dependent kinases 12 (CDK12) and 13 (CDK13) are strong candidates to combat acquired drug resistance. The long-term goal of this proposal is to develop a highly effective CDK12/13 inhibitor with an aggregate set of properties suitable to advance as a safety assessment candidate to overcome therapy resistance in both TNBC and HER2+ breast cancers and KRAS inhibitor-resistant NSCLCs. The overall objective in this application is to identify targets and pathways altered by treatment-directed CDK12/13 rewiring and develop new therapeutics that render this rewiring - an exploitable vulnerability. The central hypothesis is that CDK12/13 acts as a driver of transcriptional and post-transcriptional adaptation and that targeting CDK12/13 will block drug-induced escape and improve treatment response in breast and lung cancer. The rationale for this project posits that: (i) multiple malignancies hijack CDK12/13 to provoke transcriptional and signaling plasticity as an adaptive stress resistance mechanism, and (ii) elucidation of mechanisms underpinning compound action will offer a strong scientific framework that will facilitate future clinical development of these new agents for improved patient outcome. The central hypothesis will be tested by pursuing three Specific Aims: (1) Optimize the drug-like properties of in-house CDK12/13 specific inhibitors; (2) Define and validate the mechanisms whereby CDK12/13 inhibition prevents or reverses treatment resistance in TNBC and HER2+ breast cancers (3) Define and validate the mechanisms whereby CDK12/13 inhibition prevents or reverses KRASG12C inhibitor resistance in NSCLC. Accordingly, using a battery of approaches, we will: a) optimize key CDK12/13 inhibitor parameters to deliver a safety assessment candidate; b) define and validate the transcriptional and translational mechanisms, whereby SR-4835 provokes resensitization to chemotherapy, and c) validate cell-based observations in pre-clinical xenograft models. The research approach of our Multi-PI application is innovative, as our team has developed exceptionally selective and novel small molecule CDK12/13 in vivo active molecular probes that will enable (i) interrogation of the roles of CDK12/13 during adaptation to treatment resistance (ii) evaluation that disrupting transcriptional control will counter-resistance mechanisms providing lasting, more durable anti-cancer responses or even cures; and (iii) understanding of the critical signaling nodes that drive drug resistance. The proposed research is highly significant and provides a strong scientific rationale for the continued development of novel CDK12/13 inhibitors. We submit that insight into the molecular underpinnings of the master effectors of CDK12 and CDK13-driven signaling, together with an optimized CDK12/13 inhibitor will offer new opportunities for improved combination treatments for breast and lung cancer.
项目摘要 尽管靶向治疗的发展提高了癌症患者的总体生存率,但适应性治疗仍然存在。 肿瘤细胞的反应可使这些治疗无效。阻止自适应的代理的开发 因此,迫切需要增加治疗的持久性。我们和其他人已经证明了 转录细胞周期蛋白依赖性激酶12(CDK 12)和13(CDK 13)的抑制剂是强有力的候选者, 来对抗获得性耐药性本提案的长期目标是开发一种高效的CDK 12/13 具有适合作为安全评估候选物推进以克服 在TNBC和HER 2+乳腺癌以及KRAS肿瘤抑制剂耐药NSCLC中,整体 本申请的目的是鉴定通过治疗导向的CDK 12/13重新连接而改变的靶点和途径 并开发新的疗法,使这种重新布线-一个可利用的弱点。核心假设是 CDK 12/13作为转录和转录后适应的驱动因子,靶向CDK 12/13 将阻断药物诱导的逃逸并改善乳腺癌和肺癌的治疗反应。这样做的理由 该项目假定:(i)多种恶性肿瘤劫持CDK 12/13,以激发转录和信号可塑性 作为一种适应性的抗逆机制,以及(ii)阐明复合作用的基础机制 将提供一个强有力的科学框架,促进这些新药物的未来临床开发, 改善患者预后。中心假设将通过追求三个具体目标进行测试:(1)优化 内部CDK 12/13特异性抑制剂的药物样性质;(2)定义和验证机制 其中CDK 12/13抑制预防或逆转TNBC和HER 2+乳腺癌中的治疗抗性(3) 定义并验证CDK 12/13抑制剂阻止或逆转KRASG 12 C抑制剂的机制 NSCLC中的耐药。因此,使用一系列方法,我们将:a)优化关键的CDK 12/13抑制剂 B)定义和验证转录和翻译参数, 机制,SR-4835由此引起对化疗的再敏感,以及c)验证基于细胞的 临床前异种移植模型中的观察结果。我们的多PI应用程序的研究方法是创新的, 由于我们的团队已经开发出了非常具有选择性的新型小分子CDK 12/13体内活性分子, 探针,其将使得能够(i)在适应治疗抗性期间询问CDK 12/13的作用(ii) 评估,破坏转录控制将对抗抗性机制,提供持久的,更 持久的抗癌反应,甚至治愈;(iii)了解驱动癌症的关键信号节点。 耐药性拟议的研究非常重要,并提供了强有力的科学依据, 继续开发新型CDK 12/13抑制剂。我们提出了对分子基础的见解, CDK 12和CDK 13驱动的信号传导的主要效应物,以及优化的CDK 12/13抑制剂 将为改善乳腺癌和肺癌的联合治疗提供新的机会。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Derek Ronald Duckett其他文献

Derek Ronald Duckett的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Derek Ronald Duckett', 18)}}的其他基金

Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers
开发 CDK12 抑制剂以克服 HER2 和 KRAS 驱动的乳腺癌和肺癌的治疗耐药性
  • 批准号:
    10533580
  • 财政年份:
    2021
  • 资助金额:
    $ 66.63万
  • 项目类别:
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers
开发 CDK12 抑制剂以克服 HER2 和 KRAS 驱动的乳腺癌和肺癌的治疗耐药性
  • 批准号:
    10737865
  • 财政年份:
    2021
  • 资助金额:
    $ 66.63万
  • 项目类别:
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers
开发 CDK12 抑制剂以克服 HER2 和 KRAS 驱动的乳腺癌和肺癌的治疗耐药性
  • 批准号:
    10703529
  • 财政年份:
    2021
  • 资助金额:
    $ 66.63万
  • 项目类别:
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers
开发 CDK12 抑制剂以克服 HER2 和 KRAS 驱动的乳腺癌和肺癌的治疗耐药性
  • 批准号:
    10449355
  • 财政年份:
    2021
  • 资助金额:
    $ 66.63万
  • 项目类别:
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers
开发 CDK12 抑制剂以克服 HER2 和 KRAS 驱动的乳腺癌和肺癌的治疗耐药性
  • 批准号:
    10279337
  • 财政年份:
    2021
  • 资助金额:
    $ 66.63万
  • 项目类别:
Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma
转录和表观遗传适应作为套细胞淋巴瘤的新治疗漏洞
  • 批准号:
    10358557
  • 财政年份:
    2020
  • 资助金额:
    $ 66.63万
  • 项目类别:
Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma
转录和表观遗传适应作为套细胞淋巴瘤的新治疗漏洞
  • 批准号:
    10579255
  • 财政年份:
    2020
  • 资助金额:
    $ 66.63万
  • 项目类别:
Development of in vivo active small molecule selective inhibitors of ASK1
ASK1 体内活性小分子选择性抑制剂的开发
  • 批准号:
    9218535
  • 财政年份:
    2016
  • 资助金额:
    $ 66.63万
  • 项目类别:
High Throughput Screening to Discover Chemical Probes of ASK1
高通量筛选发现 ASK1 化学探针
  • 批准号:
    8788282
  • 财政年份:
    2013
  • 资助金额:
    $ 66.63万
  • 项目类别:
High Throughput Screening to Discover Chemical Probes of ASK1
高通量筛选发现 ASK1 化学探针
  • 批准号:
    8419212
  • 财政年份:
    2013
  • 资助金额:
    $ 66.63万
  • 项目类别:

相似国自然基金

Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 批准年份:
    2020
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 批准年份:
    2017
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 批准年份:
    2016
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 批准年份:
    2014
  • 资助金额:
    73.0 万元
  • 项目类别:
    面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
  • 批准号:
    81301123
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
  • 批准号:
    81101529
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
  • 批准号:
    39500043
  • 批准年份:
    1995
  • 资助金额:
    9.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Optogenetic and Biochemical Studies of Novel Roles of beta-Catenin Modulation/Addiction in Neuronal Differentiation and Apoptosis
β-连环蛋白调节/成瘾在神经元分化和细胞凋亡中新作用的光遗传学和生化研究
  • 批准号:
    8984020
  • 财政年份:
    2015
  • 资助金额:
    $ 66.63万
  • 项目类别:
Proteomic and Biochemical Studies of Bax Regulatory Proteins in Apoptosis
Bax 细胞凋亡调节蛋白的蛋白质组学和生化研究
  • 批准号:
    8051912
  • 财政年份:
    2010
  • 资助金额:
    $ 66.63万
  • 项目类别:
Structural/Biochemical Analysis: Apoptosis in C. elegans
结构/生化分析:线虫细胞凋亡
  • 批准号:
    7175363
  • 财政年份:
    2005
  • 资助金额:
    $ 66.63万
  • 项目类别:
Biochemical and structural characterisation of key protein interactions during apoptosis
细胞凋亡过程中关键蛋白质相互作用的生化和结构表征
  • 批准号:
    nhmrc : 356255
  • 财政年份:
    2005
  • 资助金额:
    $ 66.63万
  • 项目类别:
    Career Development Fellowships
Structural/Biochemical Analysis: Apoptosis in C. elegans
结构/生化分析:线虫细胞凋亡
  • 批准号:
    6850982
  • 财政年份:
    2005
  • 资助金额:
    $ 66.63万
  • 项目类别:
Structural/Biochemical Analysis: Apoptosis in C. elegans
结构/生化分析:线虫细胞凋亡
  • 批准号:
    7345488
  • 财政年份:
    2005
  • 资助金额:
    $ 66.63万
  • 项目类别:
Structural/Biochemical Analysis: Apoptosis in C. elegans
结构/生化分析:线虫细胞凋亡
  • 批准号:
    7011254
  • 财政年份:
    2005
  • 资助金额:
    $ 66.63万
  • 项目类别:
MITOCHONDRIA, OXIDATIVE STRESS AND NEURONAL APOPTOSIS: BIOCHEMICAL, CELLULAR AND PHARMACOLOGICAL APPROACHES
线粒体、氧化应激和神经元凋亡:生物化学、细胞和药理学方法
  • 批准号:
    nhmrc : 194323
  • 财政年份:
    2002
  • 资助金额:
    $ 66.63万
  • 项目类别:
    NHMRC Project Grants
BIOCHEMICAL DISSECTION OF P53 DEPENDENT APOPTOSIS PATHW
P53 依赖性细胞凋亡途径的生化剖析
  • 批准号:
    2885057
  • 财政年份:
    1999
  • 资助金额:
    $ 66.63万
  • 项目类别:
GENETIC AND BIOCHEMICAL EVENTS IN AB-INDUCED APOPTOSIS
AB 诱导的细胞凋亡中的遗传和生化事件
  • 批准号:
    2001588
  • 财政年份:
    1995
  • 资助金额:
    $ 66.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了